In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
US biotech firm Celgene Corp on Wednesday said its Abraxane (nab-paclitaxel) in combination with gemcitabine to treat pancreatic cancer will no longer be available via the England's Cancer Drugs Fund (CDF), starting today. 4 November 2015
UK drug major GlaxoSmithKline on Tuesday said it is looking at filing for approval of up to 20 drug candidates with regulators before 2020. 3 November 2015
French drug major Sanofi and German biotech firm BioNTech AG on Tuesday said they have entered a multi-year exclusive collaboration and license agreement to develop up to five cancer immunotherapies. 3 November 2015
The claim on Rituxan/MabThera (rituximab) intellectual property (IP) by Genentech, the biotech subsidiary of Swiss pharma giant Roche, has been dissolved by Russia’s Biocad. 3 November 2015
The US Food and Drug Administration has granted Breakthrough Therapy designation to Keytruda (pembrolizumab), US pharma giant Merck & Co’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer 3 November 2015
Australia is now offering Iclusig (ponatinib) for chronic myeloid leukemia from biopharma company Specialised Therapeutics Australia under license from Ariad Pharmaceuticals as part of the Pharmaceutical Benefits Scheme (PBS). 2 November 2015
German pharma company Merck and Poland-based Selvita have entered into a three-year collaboration to validate new therapeutic concepts in oncology. 2 November 2015
The breast cancer market will have grown to almost $20 billion across the major markets (USA, France, Germany, Italy, Spain, UK and Japan), corresponding to an impressive annual growth rate of 5%. 2 November 2015
Clinical research in its early stages relates to clinical trials of drug development in its initial steps. Its importance is high, given that it allows patients to access innovative treatments and researchers the chance to gain experience in the development of medicines, said Spain’s trade group Farmaindustria in a web posting. 2 November 2015
The Food and Drug Administration has granted Breakthrough Therapy designation to Japanese drug major Daiichi Sankyo and its US subsidiary Plexxikon’s investigational oral CSF-1R inhibitor pexidartinib. 31 October 2015
Oncology specialist Oasmia Pharmaceutical has announced that Pharmasyntez, its distribution partner in Russia and the Commonwealth of Independent States, has placed its second order for Paclical (paclitaxel) to a value of $7.5 million. 30 October 2015
Germany’s contract development and manufacturing firm ProBioGen AG and Indonesian state-owned vaccines maker Bio Farma have signed an agreement for the development of a biosimilar trastuzumab. 30 October 2015
The global treatment market for multiple myeloma will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, representing an impressive compound annual growth rate (CAGR) of 11.2%, new research indicates. 30 October 2015
French drugmaker Ipsen reported growth in sales in the third quarter of 2015 due to its Somatuline’s (lanreotide) sales increasing 33.7% year-on-year. 29 October 2015
Anglo-Swedish pharma major AstraZeneca’s drug to treat women with genetic cancers can also benefit men with advanced prostate cancer, according to a new research. 29 October 2015
The National Institute for Health and Care Excellence (NICE) has recommended against routine funding of US biotech firm Celgene Corp’s (Nasdaq: CELG) Abraxane (nab-paclitaxel), to treat pancreatic cancer saying the cost of the drug does not justified the benefits compared to current treatments. 28 October 2015
US autologous T-cell therapy product specialist Kite Pharma has entered into a worldwide research and license agreement with Alpine Immune Sciences. 28 October 2015
The US Food and Drug Administration has approved the Biologics License Application for Imlygic (talimogene laherparepvec; T-VEC), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. 28 October 2015
Telesta Therapeutics Inc on Wednesday said it has licenced its therapy to treat high risk non-muscle invasive bladder cancer (NMIBC) to Ipsen for up to $137 million in upfront and milestone payments comprising a $10 million upfront payment. 28 October 2015